Amanote Research
Register
Sign In
Schizophrenia Risk Gene CAV1 Is Both Pro-Psychotic and Required for Atypical Antipsychotic Drug Actions in Vivo
Translational Psychiatry
- United Kingdom
doi 10.1038/tp.2011.35
Full Text
Open PDF
Abstract
Available in
full text
Categories
Psychiatry
Molecular Neuroscience
Biological Psychiatry
Mental Health
Cellular
Date
August 1, 2011
Authors
J A Allen
P N Yadav
V Setola
M Farrell
B L Roth
Publisher
Springer Science and Business Media LLC
Related search
Chlorpromazine Versus Atypical Antipsychotic Drugs for Schizophrenia
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Molecular Psychiatry
Psychiatry
Molecular Neuroscience
Mental Health
Molecular Biology
Cellular
Schizophrenia Polygenic Risk Score and Psychotic Risk Detection
The Lancet Psychiatry
Psychiatry
Biological Psychiatry
Mental Health
Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
International Journal of Molecular Sciences
Organic Chemistry
Molecular Biology
Theoretical Chemistry
Inorganic Chemistry
Computer Science Applications
Spectroscopy
Medicine
Catalysis
Physical
Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics
BMC Psychiatry
Psychiatry
Mental Health
Pharmacoeconomic Comparison of Ziprasidone With Other Atypical Oral Antipsychotic Agents in Schizophrenia
Farmeconomia. Health economics and therapeutic pathways
What Is the Risk-Benefit Ratio of Long-Term Antipsychotic Treatment in People With Schizophrenia?
World Psychiatry
Psychiatry
Mental Health
Psychiatric Mental Health
Microglial Intracellular Ca2+ Signaling as a Target of Antipsychotic Actions for the Treatment of Schizophrenia
Frontiers in Cellular Neuroscience
Molecular Neuroscience
Cellular
Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia
Frontiers in Psychiatry
Psychiatry
Mental Health
